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siRNA deliveryWhile the delivery of small interfering RNAs (siRNAs) is an attractive strategy to treat several clinical con-
ditions, siRNA-nanocarriers’ stability after intravenous administration is still a major obstacle for the
development of RNA-interference based therapies. But, although the need for stability is well recognized,
the notion that strong stabilization can decrease nanocarriers’ efﬁciency is sometimes neglected. In this
work we evaluated two stealth functionalization strategies to stabilize the previously validated dioctade-
cyldimethylammonium bromide (DODAB):monoolein (MO) siRNA-lipoplexes. The nanocarriers were
pre- and post-pegylated, forming vectors with different stabilities in biological ﬂuids. The stealth
nanocarriers’ behavior was tested under biological mimetic conditions, as the production of stable
siRNA-lipoplexes is determinant to achieve efﬁcient intravenous siRNA delivery to cancer cells. Upon
incubation in human serum for 2 h, by ﬂuorescence Single Particle Tracking microscopy, PEG-coated lipo-
plexes were found to have better colloidal stability as they could maintain a relatively stable size. In addi-
tion, using ﬂuorescence ﬂuctuation spectroscopy, post-pegylation also proved to avoid siRNA dissociation
from the nanocarriers in human serum. Concomitantly it was found that PEG-coated lipoplexes improved
cellular uptake and transfection efﬁciency in H1299 cells, and had the ability to silence BCR-ABL, affecting
the survival of K562 cells.
Based on an efﬁcient cellular internalization, good silencing effect, good siRNA retention and good col-
loidal stability in human serum, DODAB:MO (2:1) siRNA-lipoplexes coated with PEG-Cer are considered
promising nanocarriers for further in vivo validation.
Statement of Signiﬁcance
Thiswork describes two stealth functionalization strategies for the stabilization of the previously validated
dioctadecyldimethylammoniumbromide (DODAB):monoolein (MO) siRNA-lipoplexes. These nanocarriers
are capable of efﬁciently incorporating and delivering siRNA molecules to cells in order to silence genes
whose expression is implicated in a pathological condition. The main objective was to functionalize these
nanocarriers with a coating conferring protection to siRNA in blood without compromising its efﬁcient
delivery to cancer cells, validating the potential of DODAB:MO (2:1) siRNA-lipoplexes as therapeutic vec-
tors.We show that the stealth strategy is determinant to achieve a stable and efﬁcient nanocarrier, and that
DODAB:MO mixtures have a very promising potential for systemic siRNA delivery to leukemic cells.
 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.monium
rescence
ethylene
Table 1
Nucleic acid sequences used in the silencing experiments. Sense strands are
represented. Lower case letters represent 20-deoxyribonucleotides.
siEGFP 50-CAAGCUGACCCUGAAGUUCtt-30
siCTRL 50-UGCGCUACGAUCGACGAUGtt-30
siBCR-ABL 50-AAGGGCUUUUGAACUCUGCtt-30
siSCRAMB 50-GUCUCAAGUUUUCGGGAAGtt-30
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RNA interference (RNAi) is a natural mechanism by which short
interfering RNAs (siRNAs) speciﬁcally inhibit protein synthesis [1].
The remarkable potential of this silencing mechanism has made
siRNA therapy an important area in the biomedical ﬁeld over the
past years [2–7]. The scientiﬁc focus has not only been devoted
to designing efﬁcient siRNA molecules [8] but also to develop
methods to deliver siRNAs to their site of action [9]. The develop-
ment of nanocarriers has been the strategy of choice to provide
protection, improve internalization by target cells and to optimize
the intracellular trafﬁcking of therapeutic siRNA molecules [9–12].
The design of nanocarriers for siRNA delivery must take into
account properties such as small and uniform size distribution to
allow internalization by endocytosis, and the ability to protect the
encapsulated siRNA from enzymatic degradation. Biocompatibility
and stability are additional requirements [2,9,13,14]. Systemic
administration poses additional challenges to the nanocarriers, as
interaction with serum proteins might induce premature release
of siRNA and prompt aggregation [15–19]. Extended circulation
times of stabilized delivery systems in the bloodstream has been
mainly achieved by coating their surface with poly(ethylene glycol)
(PEG). PEG is a highly soluble neutral polymer that forms a protec-
tive hydrophilic layer at the nanocarriers surface, providing a ‘‘steric
stabilization’’ effect that changes the surface properties, reduces
opsonization by blood proteins, and decreases uptake by phagocytic
cell populations [20,21]. Steric stabilizationcanbe achievedbyother
polymers besides PEG [22], but pegylation is still the most popular
strategy to increase the circulation time of nanocarriers. Yet, steric
stabilization provided by PEG was found to be undesirable during
certain phases of the drug/nucleic acid delivery process. Pegylated
nanocarriers might not satisfactorily protect nucleic acids against
enzymatic degradation, and PEG can prevent nanocarriers cellular
uptake or hinder siRNA endosomal escape [16,23–26]. To overcome
these issues, exchangeable PEG-derivatives such as PEG-ceramides
(PEG-Cer) have been proposed as a semi-stable coating, to provide
good initial protection and stability in blood, while maintaining
good cellular uptake and transfection [27]. Dissociation of the
PEG-Cer chains from the siRNAnanocarrierwill improve interaction
with the cell membrane, cellular internalization and escape from
endosomal compartments. However, it is not only the type of PEG
that inﬂuences the transfection efﬁciency outcome, but also the
pegylationmethod. Peeters et al. [23] prepared stealth nanocarriers
by pre- and post-pegylation with PEG-Cer. The authors found that,
even though the same type of PEG was used in both strategies,
pre-pegylation of lipoplexes inhibited transfection efﬁciency due
to slower internalization and entrapment inside endosomes, while
post-pegylation improved transfection efﬁciency. Moreover, these
and other authors have also shown that post-pegylation with
DSPE–PEG leads to very low transfection efﬁciencies [23,25].
Recent work from our group has shown that liposomes pre-
pared with dioctadecyldimethylammonium bromide (DODAB)
and monoolein (MO) (DODAB:MO) are promising carriers for
pDNA delivery [28–31]. The presence of MO on the formulation
was found to be advantageous due to an increased ﬂuidiﬁcation
of the nanocarrier membranes and stabilization of the liposomal
structures [29,32,33]. DODAB:MO liposomes were also found to
be suitable for siRNA delivery, as they efﬁciently encapsulated
siRNA, were extensively taken up by the cells and were able to
silence GFP expression without inducing cytotoxicity [34]. With
this work we aimed to optimize the previously developed
DODAB:MO (2:1) formulation for siRNA systemic delivery, by
improving the nanocarriers’ performance in physiological condi-
tions. Taking previous reports into account [23,25], we have com-
pared pre- and post-pegylation strategies in terms of stability inserum and capability to transfect cells. For pre-pegylation, DSPE–
PEG was added to the liposomes before complexation with
siRNA. For post-pegylation, PEG-Cer was inserted into the already
formed siRNA lipoplexes.
Advanced ﬂuorescence microscopy techniques such as ﬂuores-
cence Single Particle Tracking (fSPT) and ﬂuorescence ﬂuctuation
spectroscopy (FFS) were used to characterize the stability of the
nanocarriers and protection of siRNA in human serum [15,16,18].
Fluorescence spectroscopy was additionally used to assess if the
presence of PEG inﬂuences the binding of human serum proteins
to the liposomes. Gene silencing efﬁciency and cellular internaliza-
tion were also evaluated and correlated with the nanocarriers’
properties. The therapeutic potential of the siRNA-lipoplexes was
further determined in a leukemia cell line model.2. Materials and methods
2.1. Materials
Dioctadecyldimethylammonium bromide (DODAB),
1-monooleoyl-rac-glycerol (MO), dextran sulfate sodium salt,
bovine serum albumin (BSA), and human serum albumin (HSA)
were purchased from Sigma–Aldrich (Bornem, Belgium).
Poly(ethylene glycol)2000–distearoyl-phosphatidylethanolamine
(DSPE–PEG) and poly(ethylene glycol)2000 C(8)ceramide (PEG-Cer)
were supplied by Avanti Polar Lipids (Alabaster, AL, USA).
RPMI-1640 and Opti-MEM cell culture mediums, L-Glutamine,
Fetal Bovine Serum (FBS), Trypsin–EDTA solution, Penicillin–
Streptomycin (5000 IU/ml penicillin and 5000 lg/ml strepto-
mycin), Geneticin and phosphate-buffered saline (PBS) were
ordered from Gibco (UK). Hoechst n 33342, Lipofectamine
RNAiMAx and 1,10-Dioctadecyl-3,3,30,30-Tetramethylindodicarbo
cyanine Perchlorate oil (DiIC18(5) oil) (kexc = 644 nm; kem = 665 nm)
were purchased from Invitrogen (Merelbeke, Belgium). LysoSensor
Green was ordered from Molecular Probes (Merelbeke, Belgium).
SV Total RNA Isolation System and CellTiter 96 AQueous One
Solution Cell Proliferation Assay were obtained from Promega
(Madison, USA). MTT assay was ordered from Roche (Germany).
iScript™ Reverse Transcription Supermix for RT-qPCR and the
iTaq™ Universal SYBR Green Supermix were purchased from
Bio-Rad (USA). siRNA targeting the enhanced green ﬂuorescent pro-
tein (siEGFP) and a universal negative control duplex (siCTRL) were
obtained from Eurogentec (Seraing, Belgium). Confocal microscopy
and uptake experiments were performed with a Cy5-labeled
siRNA duplex (Eurogentec, Seraing, Belgium). siRNA targeting the
BCR-ABL protein (siBCR-ABL) and a scrambled sequence
(siSCRAMB) were purchased from IDT (Iowa, USA). The nucleic
acids sequences are shown in Table 1. siRNAs were prepared at
20 lM in DEPC-treated water and stored at 20 C until used.
2.2. Preparation of liposomes and siRNA-lipoplexes
In order to coat the nanocarriers, cationic liposomes composed
by DODAB:MO (molar ratio 2:1 (mol:mol)) and DSPE–PEG were
prepared by a pre-pegylation methodology. Brieﬂy, deﬁned
Fig. 1. Structure of the lipids used during this work.
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DSPE–PEG (1 mg mL1 stock solution in chloroform) were placed
in a round-bottomed ﬂask and the solvents evaporated under vac-
uum at 40 C. The lipid ﬁlm was hydrated (>50 C) with 1 mL
HEPES buffer (25 mM pH 7.4) to a ﬁnal total lipid concentration of
5 mM, forming PEG 0%/DODAB:MO, PEG 5%/DODAB:MO, PEG
10%/DODAB:MO, and PEG 15%/DODAB:MO liposomes, herein
referred as Peg0, Peg5, Peg10, and Peg15 liposomes. Finally, lipo-
somes were extruded at room temperature (RT) 11 times through
a 100 nm pore sized polycarbonate membrane (Whatman, USA)
using the Avanti Polar Lipids Mini-extruder. siRNA-lipoplexes incor-
porating DSPE–PEG were prepared by incubation of siRNA (diluted
in HEPES buffer, 25 mM pH 7.4) with an equal volume of liposomes,
at the deﬁned lipid concentration to form the desired charge ratio
(+/). siRNA-lipoplexes were incubated for 20 min at RT before use.
Liposomes and siRNA-lipoplexes composed by DODAB:MO
(2:1) were also prepared with PEG-Cer by post-pegylation.
Brieﬂy, liposomes DODAB:MO (2:1) were formed, and
DODAB:MO (2:1) (+/) 15 lipoplexes were prepared by the incuba-
tion of siRNA with liposomes, as described. Subsequently, deﬁned
volumes of PEG-Cer (1 mg mL1 stock solution in chloroform) were
added to the liposomes or siRNA-lipoplexes and incubated for 1 h
at 60 C, for the integration of the PEG-Cer chains onto the liposo-
mal membranes. PEG-Cer 0%/DODAB:MO, PEG-Cer 5%/DODAB:MO,
PEG-Cer 10%/DODAB:MO and PEG-Cer 15%/DODAB:MO liposomes,
or siRNA-lipoplexes at charge ratio (+/) 15 were obtained, which
will be referred as PegCer0, PegCer5, PegCer10, and PegCer15 lipo-
somes or siRNA-lipoplexes, for simpliﬁcation.% free siRNA ¼ ðfree siRNA BLmedium BLÞ  ðfree siRNA BL complexed siRNAÞðfree siRNA BLmedium BLÞ  100 ð1ÞThe chemical structures of the lipids used during this work are
shown in Fig. 1.2.3. Dynamic light scattering (DLS) and zeta (f)-potential
Dynamic light scattering (DLS) was used to determine the mean
size, polydispersity index (PDI) and surface charge of liposomes
and siRNA-lipoplexes. Liposomes were measured in HEPES buffer,
25 mM pH 7.4, at a ﬁnal lipid concentration of 1 mM, and
siRNA-lipoplexes were prepared with 200 nM siCTRL.
Measurements were made at 25 C in a Zetasizer Nano ZS(Malvern, UK), equipped with Dispersion Technology Software
(DTS). All results were based on intensity distributions.2.4. Scanning transmission electron microscopy (STEM)
Peg0, Peg10, PegCer0 and PegCer10 liposomes were analyzed by
Field Emission Gun Scanning Electron Microscopy (FEG-SEM).
Liposomes were installed in Cu-C grids (S160-4 AGAR) by immer-
sion in the solution, and morphological analyses were realized in
an Ultra-high resolution FEG-SEM, NOVA 200 Nano SEM, FEI
Company. An acceleration voltage of 17.5 kV and a Scanning
Transmission Electron Detector (STEM) were used.2.5. Fluorescence ﬂuctuation spectroscopy (FFS)
The amount of siRNA released from the siRNA-lipoplexes, when
dispersed in human serum (HS), was determined by ﬂuorescence
ﬂuctuation spectroscopy (FFS) as previously described
[15,16,19,35]. In FFS, ﬂuorescence intensity ﬂuctuations are moni-
tored in the focal volume (1 fL) of a confocal microscope as a
function of time. Free ﬂuorescently labeled siRNA molecules give
rise to a certain ‘baseline’ intensity, while intense ﬂuorescence
peaks are observed when siRNA-lipoplexes (containing many
molecules of ﬂuorescent siRNAs) diffuse in and out of the focal vol-
ume (Supplementary information, Fig. S1). The percentage of
siRNA that is released upon incubation of the lipoplexes in serum
can be quantiﬁed according to Eq. (1) [16]:where free siRNA BL is the siRNA baseline ﬂuorescence signal if all
siRNA is free (positive control), medium BL is the baseline signal
recorded from samples dispersed in the medium of interest, and
complexed siRNA is the ﬂuorescence signal associated with the ini-
tial stock solution of siRNA-lipoplexes (negative control).
FFS measurements were performed to determine the extent of
siRNA release from siRNA-lipoplexes when dispersed in HS.
siRNA-lipoplexes were prepared with 50 nM Cy5-siRNA in
HEPES buffer, and incubated in 50% HS (lipoplexes:HS 50:50 v:v)
at 37 C to determine siRNA release over time. siRNA baseline sig-
nals were obtained by measuring the ﬂuorescence of free
Cy5-siRNA in 50% HS or HEPES buffer, and the background
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HEPES buffer alone. Measurements were made at deﬁned time
points on a Nikon C1 confocal laser scanning microscope (Nikon
Belux, Brussels, Belgium) equipped with a Plan Apo VC 60 1.2
NA water immersion objective lens with collar rim correction.
The laser was focused at about 100 lm above the bottom of a
glass-bottom 96-well plate (Greiner Bio-one, Frickenhausen,
Germany), and measurements of 30 s were performed.
2.6. Fluorescence Single Particle Tracking (fSPT)
siRNA-lipoplexes aggregation in full HS was followed by ﬂuo-
rescence Single Particle Tracking (fSPT) as a function of time [18].
Brieﬂy, ﬂuorescent DiIC18(5) oil-labeled DODAB:MO (2:1) (1%
mol:mol) liposomes were used to form siRNA-lipoplexes at charge
ratio (+/) 15 (250 nM siCTRL), and PEG-Cer was incorporated as
described. Different pegylation degrees (0%, 5%, 10% and 15%) were
tested. siRNA-lipoplexes were subsequently diluted in HEPES buf-
fer (1:20 v:v) and incubated in full HS at 37 C. For each time point,
7 lL of the sample was placed in a microscope slide and covered
with a cover glass, using a double-sided adhesive sticker of
120 lm thickness (Secure-Seal Spacer, Molecular Probes, Leiden,
The Netherlands) to create a closed chamber. The microscope
was focused between 5 and 10 lm from the cover glass and 20
movies of 10 s each were recorded at different locations within
the sample. A custom-built laser wideﬁeld epi-ﬂuorescence micro-
scope set-up, with a TE2000-E inverted microscope equipped with
a Nikon Plan Apo VC 100 1.4 NA oil immersion objective lens
(Nikon Belux, Brussels, Belgium) was used for the fSPT measure-
ments. siRNA-lipoplexes were excited with a 636 nm diode laser
(IQ1C, Power Technology, Little Rock, AR), and the red emission
channel was deﬁned in the spectral range between 655 and
745 nm. Images were registered with an EMCCD camera (Cascade
II:512, Roper Scientiﬁc, Tucson, AZ) synchronized with an
acousto-optical tunable ﬁlter (AOTF), to illuminate the sample only
during the camera exposure time, minimizing this way potential
photobleaching. The image acquisition was done with the NIS
Elements imaging software (Nikon Belux, Brussels, Belgium) at a
frame speed of 33 frames per second and exposure times of
10 ms. The analysis of fSPT movies was performed off-line, as pre-
viously reported [18]. Brieﬂy, trajectories were calculated using the
nearest neighbor algorithm, and the mean diffusion coefﬁcient was
obtained for each trajectory using an algorithm based on the mean
square displacement analysis. Using the Stokes–Einstein equation,
the distribution of the diffusion coefﬁcients was transformed in a
size distribution, and the actual size distribution was ﬁnally
obtained using a Maximum Entropy deconvolution process.
2.7. Fluorescence spectroscopy (FS)
Fluorescence spectroscopy (FS) was used to evaluate the effect
of PEG-Cer on the binding of human serum albumin (HSA) to lipo-
somes, and the binding constant (Kb) and the free energy of Gibbs
(DG) were determined for three temperatures, according to
Copeland et al. [36] (Supplementary information, Fig. S2). Brieﬂy,
HSA protein solutions (18 lM in HEPES buffer, pH 7.4 25 mM) were
incubated with increasing concentrations of liposomes, and the
ﬂuorescence emission spectra (300–450 nm) were recorded in a
Horiba Jobin Yvon Spex Fluorolog-3 spectroﬂuorimeter, using a
kexc = 291 nm, with spectral bandwidths of 1 nm, at 25, 30 and
37 C.
FS was also used to evaluate the interaction of siRNA-lipoplexes
with the serum proteins ﬁbrinogen, globulins and HSA, by trypto-
phan ﬂuorescence emission, as described elsewhere [37]. Brieﬂy,
protein solutions (1000, 350 and 800 lg mL1 of HSA, ﬁbrinogenand globulins, respectively), prepared in PBS, were incubated with
siRNA-lipoplexes (50 nM siCTRL) at a ratio 98:2 (v:v). Fluorescence
emission spectra (300–450 nm) were recorded in a Wallac
Enviosin plate reader (Perkin–Elmer) using a kexc = 270 nm, with
spectral bandwidths of 2 nm. For every measurement, two spectra
were recorded and the average calculated using the FluorEssence
TM software. The measured signal was normalized, so that the
spectral shift could be better visualized.
2.8. Cell lines and culture conditions
Several cell lines: K562, H1299 wild type (H1299 wt) and
H1299 stably expressing enhanced green ﬂuorescent protein
(H1299 eGFP) were grown in RPMI 1640 cell culture medium sup-
plemented with 1% L-glutamine, 10% FBS and 2% penicillin–strepto
mycin. Cells were maintained in a humidiﬁed incubator, at 37 C
and 5% CO2. H1299 cells were passed every 3 days using 0.05%
Trypsin–EDTA solution, and H1299 eGFP cells were additionally
treated with 1 mg mL1 Geneticin once per month for selection.
K562 cells were passed every 3–4 days at a cell density 0.5  105 -
cells mL1 to maintain sub-conﬂuency.
2.9. Flow cytometry
Flow cytometry was used for the evaluation of EGFP gene
silencing on H1299 eGFP cells and for the quantiﬁcation of
siRNA-lipoplexes cellular uptake. For the EGFP gene silencing eval-
uation, H1299 eGFP cells were seeded on 24-multiwell plates at a
density of 35  105 cells per well and grown overnight. Complete
cell culture medium was replaced by Opti-MEM and 100 lL of
siRNA-lipoplex solutions (with 50 nM siCTRL or 50 nM siEGFP)
was added. After 4 h incubation, Opti-MEM was replaced by fresh
cell culture medium, and cells were further incubated for 44 h at
37 C and 5% CO2. Finally, cells were washed with PBS, trypsinized
(0.25% trypsin–EDTA) and diluted with 1 mL complete cell culture
medium. After centrifugation (1400 rpm, 7 min), the cell pellet was
resuspended in 300 lL ﬂow buffer (1% BSA and 0.1% sodium azide
in PBS) and kept on ice until EGFP expression was quantiﬁed using
a Beckman Coulter Cytomics FC500 ﬂow cytometer equipped with
an argon laser (excitation at 488 nm). The silencing experiments
were performed in triplicate and 20  103 cells were considered
for each sample. The percentage of downregulation was expressed
according to Eq. (2):
%Downregulation ¼ ð1 siEGFP=siCTRLÞ  100 ð2Þ
where siEGFP and siCTRL are the mean EGFP ﬂuorescence intensity
of cells treated with siRNA-lipoplexes prepared with siEGFP and
siCTRL, respectively.
For the siRNA-lipoplexes uptake experiments, H1299 eGFP cells
were seeded into 24-multiwell plates at a density of 35  105 cells
per well and grown overnight. After the complete cell culture med-
ium was replaced by Opti-MEM, 100 lL siRNA-lipoplexes pre-
pared with 50 nM siCTRL (2% Cy5-labeled siRNA) was added to
each well. After 4 h incubation at 37 C, cells were washed with
0.1 mg mL1 dextran sulfate solution for 5 min to remove
non-internalized siRNA-lipoplexes and further prepared for analy-
sis as described for the gene silencing assay (excitation of Cy5 at
633 nm). Experiments were performed in triplicate and 10  103
cells were considered for each sample.
2.10. Confocal laser scanning microscopy (CLSM)
H1299 cells were seeded on glass bottomed 35 mm cell culture
dishes (Greiner, Germany) at a cell density of 1.25  105 cells per
dish and grown overnight. Complete cell culture medium was
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siRNA-lipoplexes (50 nM siRNA, 50% Cy5-labeled siRNA and 50%
siCTRL) for 4 h at 37 C. After the incubation period, a washing step
with 0.1 mg mL1 dextran sulfate solution was performed to
remove the non-internalized siRNA-lipoplexes. PBS was then used
to remove dextran sulfate and complete cell culture medium was
added to the cells. Cells were observed on a Nikon C1 confocal laser
scanning microscope (Nikon Belux, Brussels, Belgium) equipped
with a Plan Apo VC 60 1.2 NA water immersion objective lens.
Cell nucleus was stained with Hoechst n 33342 (1 lM, 15 min)
and endo-lysosomal compartments with LysoSensor Green
(1 lM, 1 h).Fig. 2. Schematic representation of the two pegylation strategies studied.2.11. Quantitative real time PCR (qPCR)
Quantitative real time PCR (qPCR) was used to evaluate knock-
down of the BCR-ABL gene in the K562 cell line. K562 cells were
seeded on 12-multiwell plates, at a cell density of 1  105 cells
per well, in RPMI cell culture medium without FBS, and 100 lL
of siRNA-lipoplex solutions, prepared with 100 nM siSCRAMB or
100 nM siBCR-ABL, were immediately added to each well.
Lipofectamine RNAiMax lipoplexes (100 nM siRNA) were used
as a control, and prepared according to manufacturer’s instruc-
tions. After 4 h incubation, RPMI was replaced by complete cell
culture medium, and cells were further incubated for 20 h at
37 C and 5% CO2. Total RNA from transfected cells was isolated
and puriﬁed using the SV Total RNA Isolation System (Promega,
Madison, USA) according to manufacturer’s instructions. RNA qual-
ity and concentration were veriﬁed in the NanoDrop ND1000
Spectrophotometer (Thermo Scientiﬁc). Total RNA (275 ng) was
converted into cDNA using the iScript™ Reverse Transcription
Supermix for RT-qPCR (Bio-Rad, USA), according to instructions.
The following protocol was used: 1st step, 5 min at 25 C; 2nd step,
60 min at 42 C; 3rd step, 5 min at 85 C. cDNA was used for qPCR
analysis using iTaq™ Universal SYBR Green Supermix (Bio-Rad,
USA) in the CFX96™ Real-Time PCR System (Bio-Rad). Puriﬁed
salt-free primers for target gene BCR-ABL (forward primer 50-TCC
GCTGACCATCAATAAGGA-30 and reverse primer 50-CACTCAGACCC
TGAGGCTCAA-30) and for the reference gene GADPH (forward pri-
mer 50-AGGTCGGTGTGAACGGATTTG-30 and reverse primer 50-TG
TAGACCATGTAGTTGAGGTCA-30) were generated. The qPCR reac-
tion was performed in 96-well PCR plates (iCycler iQ, Bio-Rad) as
follows: one cycle of 30 s at 95 C, followed by 40 PCR cycles at
95 C  5 s and 61 C  30 s. A melting curve was made immedi-
ately after the qPCR, to demonstrate the speciﬁcity of the ampliﬁ-
cation, consisting in 1 cycle of 95 C  60 s and 55 C  60 s,
followed by an increase in temperature from 55 to 95 C, with
0.5 C increments in each step. No template controls were always
evaluated for each target gene. Relative gene expression values
were determined according to Pfafﬂ 2001 [38]. Quantiﬁcation cycle
(Cq) values were generated automatically by the Bio-Rad CFX
Manager 2.0 Software, and the ratio of the target gene BCR-ABL
was expressed in comparison to the reference gene GADPH, accord-
ing to Eq. (3):
ratio ¼ E
DCqtarget
target
E
DCqref
ref
; ð3Þ
where Etarget is the real-time PCR efﬁciency of the BCR-ABL tran-
script; Eref is the real-time PCR efﬁciency of the GADPH reference
gene transcript; DCqtarget = Cqcontrol  Cqsample of the target gene
transcript; and DCqref = Cqcontrol  Cqsample of the reference gene
transcript. Real-time PCR efﬁciencies were calculated according to
E = 10(1/slope), and were found to be between 95% and 115%, with
R2 > 0.99.2.12. Cell survival assays
Cytotoxicity assays were performed to determine the percent-
age of H1299 eGFP viable cells after incubation with
siRNA-lipoplexes, as well as to evaluate the effect of the BCR-ABL
downregulation on K562 cell survival. Brieﬂy, H1299 eGFP cells
were seeded into 24-multiwell plates at a density of 35  105 cells
per well and grown overnight. The complete cell culture medium
was replaced by Opti-MEM and 100 lL of siRNA-lipoplex solu-
tions (50 nM siCONTROL) were added to each well. After a 4 h incu-
bation period at 37 C, 5% CO2, the supernatant was removed and
replaced by fresh cell culture medium. After 44 h cell viability
was assessed with the MTT assay. K562 cells were seeded on
96-multiwell plates, at a cell density of 1  105 cells per well, in
RPMI cell culture medium without FBS. DODAB:MO (2:1)
nanocarriers were added to the cells as described above, with
100 nM siSCRAMB, 100 nM siBCR-ABL, or as empty liposomes.
Lipofectamine RNAiMax was used as control. After 72 h cell via-
bility was assessed with the CellTiter 96 AQueous One Solution
Cell Proliferation Assay according to manufacturer’s instructions.
Non-treated (NT) cells were set to 100% cell survival. The percent-
age of effective cell survival was determined by normalizing the
cytotoxicity obtained after treatment with siBCR-ABL lipoplexes
against the empty vectors’ cytotoxicity.
2.13. Statistical analysis
Statistical analysis was performed with GraphPad Prism 5.0
Software. The one-way ANOVA test was used followed by a
Dunnett’s post-test. Results were expressed as mean ± standard
deviation (S.D.). Statistical signiﬁcance is highlighted as follow:
*p 6 0.05, **p 6 0.01, ***p 6 0.001.3. Results
3.1. Pegylation strategy does not signiﬁcantly affect the nanocarriers
physicochemical characteristics
DODAB:MO (2:1) liposomes were previously validated for
pDNA and siRNA delivery, showing a good transfection activity
without inducing signiﬁcant cytotoxicity [28,30,34]. In this study
Table 2
Physicochemical characterization of liposomes and siRNA-lipoplexes. Averaged mean size (nm), PDI and f-potential (mV) of liposomes and lipoplexes (charge ratio (+/) 15)
prepared with different percentages of DSPE–PEG and PEG-Cer (0%, 5% 10% and 15%), in HEPES buffer (25 mM pH 7.4). siRNA ﬁnal concentration in lipoplexes: 200 nM. Values are
the average ± S.D. of 3 measurements on the same sample.
% of PEG Liposomes siRNA-lipoplexes
Mean size PDI f-Potential Mean size PDI f-Potential
DSPE–PEG (pre-pegylation) Peg0 116 ± 1 0.11 ± 0.02 49 ± 1 135 ± 1 0.13 ± 0.01 47 ± 1
Peg5 124 ± 1 0.09 ± 0.01 19 ± 1 137 ± 1 0.11 ± 0.03 15 ± 1
Peg10 124 ± 2 0.09 ± 0.02 17 ± 2 129 ± 1 0.10 ± 0.01 14 ± 5
Peg15 111 ± 0 0.11 ± 0.02 10 ± 0 117 ± 3 0.18 ± 0.02 10 ± 0
PEG-Cer (post-pegylation) PegCer0 106 ± 1 0.12 ± 0.01 56 ± 2 137 ± 1 0.18 ± 0.02 55 ± 2
PegCer5 118 ± 1 0.12 ± 0.01 32 ± 1 130 ± 1 0.20 ± 0.01 26 ± 3
PegCer10 121 ± 1 0.12 ± 0.02 31 ± 1 127 ± 2 0.12 ± 0.00 27 ± 0
PegCer15 124 ± 2 0.11 ± 0.02 20 ± 2 126 ± 1 0.13 ± 0.01 15 ± 1
A.C.N. Oliveira et al. / Acta Biomaterialia 25 (2015) 216–229 221we have chosen two stealth functionalization strategies combining
two pegylation methods (pre- or post-pegylation) to optimize
siRNA encapsulation and protection in serum (Fig. 2). Our aim is
to obtain a coating able to provide good encapsulation and protec-
tion to siRNA in blood but at the same time allowing an efﬁcient
siRNA delivery to cancer cells, validating the potential of
DODAB:MO (2:1) siRNA-lipoplexes as therapeutic vectors.
Theeffectof the twostabilizationapproachesonthemeansize and
surface chargeofDODAB:MO(2:1) liposomesand siRNA-lipoplexes is
shown in Table 2 and Fig. 3. Before characterization, siRNA encapsu-
lation was assessed by a gel retardation assay, and all liposomal for-
mulations were found to entirely encapsulate the siRNA at charge
ratio (+/) 15 (Supplementary information, Fig. S3).
With both strategies, the surface charge of liposomes and
siRNA-lipoplexes decreased with increasing percentage of grafted
PEG, although a positive surface charge could still be measured
for the higher percentage of PEG tested (>+10 mV). The heating
step required for the incorporation of PEG-Cer chains on the lipo-
somal membranes slightly inﬂuenced the surface charge of lipo-
somes: f-potential of +49 mV for Peg0 liposomes (no heating),
and +56 mV for PegCer0 liposomes (heating at 60 C for 1 h for
the incorporation of the PEG-Cer chains). The same trend was
observed for siRNA-lipoplexes. Table 2 shows that all formulations
have a homogeneous size distribution (PDI <0.2). Furthermore,
they present mean sizes bellow 140 nm, and the size of the
nanocarriers did not appreciably change by the pegylation process.
Fig. 3 shows STEM micrographs of selected liposome dispersions,
conﬁrming that small and homogeneous populations are obtained.
No signiﬁcant aggregation was detected for all the samples.
3.2. Pegylation strategy inﬂuences lipoplex stability in physiological
conditions and interaction with human serum proteins
Once nanocarriers are administered intravenously, as required
for treatment of pathologies such as leukemia, they immediately
come into contact with blood constituents, including cells such
as erythrocytes, platelets and leukocytes, or plasma proteins.
Such interactions can not only trigger cellular immune responses,
but also alter the physicochemical characteristics of the nanocarri-
ers, compromising their efﬁciency. The binding of serum proteins
to nanocarriers is a main driving force for aggregation and prema-
ture release of the nanocarriers’ payload, signiﬁcantly decreasing
its possibility of success. Therefore, the study of the interface
between nanocarriers and serum constituents is essential for the
development of any systemic drug or nucleic acid delivery system.
We performed a detailed evaluation of the stability of DODAB:MO
(2:1) siRNA-lipoplexes in human serum (HS) by quantifying siRNA
dissociation from siRNA-lipoplexes by ﬂuorescence ﬂuctuation
spectroscopy (FFS) and siRNA-lipoplexes aggregation by ﬂuores-
cence Single Particle Tracking (fSPT) (Fig. 4).siRNA dissociation measurements were made immediately
after incubation of Cy5-labeled siRNA-lipoplexes with HS (0 h),
and after 1 h and 2 h incubation (Fig. 4A and B). Fig. 4A shows that,
although free siRNA was detected in all samples prepared in HEPES
buffer, pegylation with DSPE–PEG resulted in slightly higher values
of uncomplexed siRNA. Actually, as the percentage of DSPE–PEG
increased, more non-encapsulated siRNA could be detected
(Fig. 4A), going from 10% to 18% detected free siRNA. The oppo-
site was observed for PEG-Cer (Fig. 2B), with non-encapsulated
siRNA going from 6% to 3% with the increase in PEG-Cer percent-
age. When siRNA-lipoplexes were incubated in HS, siRNA release
was immediately observed, increasing gradually over time for all
the samples (Fig. 4A and B). Nevertheless, pegylation with DSPE–
PEG resulted in higher siRNA release from the system when com-
pared to pegylation with PEG-Cer. The presence of higher percent-
ages of DSPE–PEG promoted siRNA dissociation: after 2 h
incubation, 65% siRNA was displaced from Peg0 lipoplexes, while
85% was released from Peg15 lipoplexes. The effect of the heating
step required for the incorporation of PEG-Cer in the
siRNA-lipoplexes inﬂuenced the stability of the nanocarriers, since
less siRNA was released from PegCer0 lipoplexes when compared
to Peg0 lipoplexes (no heating) for all the time points. siRNA disso-
ciation from PEG-Cer siRNA-lipoplexes was always less than 50%,
even after 2 h incubation in HS (Fig. 4B).
Since PEG-Cer siRNA-lipoplexes provided the best protection of
siRNA in serum (Fig. 4A versus B), further experiments were per-
formed to test their colloidal stability, because this could be com-
promised by a fast dissociation of the PEG moieties from liposome
bilayers. Aggregation of DODAB:MO (2:1) siRNA-lipoplexes in HS
was determined by fSPT, and the siRNA-lipoplex size distributions,
obtained according to Section 2.7 in materials and methods, are
shown in Fig. 4C and D. A clear difference in size distribution
between pegylated and non-pegylated siRNA-lipoplexes could be
observed immediately after incubation of the nanocarriers with
HS (Fig. 4C versus D, Control (t0h) – gray lines). Non-pegylated
nanocarriers (Fig. 4C, gray line) show a much broader size distribu-
tion than pegylated ones (Fig. 4D, gray line), compatible with a
more homogeneous population of smaller nanocarriers in the lat-
ter. After 2 h incubation in HS (Fig. 4C and D, dark lines), pegylated
lipoplexes maintained better colloidal stability (mean sizes 140 to
150 nm) than non-pegylated lipoplexes (mean size >200 nm),
independently of the PEG-Cer percentage.
In order to determine if the presence of PEG-Cer on the lipo-
some surface can reduce interaction with proteins, the binding of
HSA to non-pegylated and pegylated liposomes was evaluated by
ﬂuorescence spectroscopy (FS) (Fig. 5A and B). Additionally, we
evaluated if interaction with siRNA-lipoplexes might induce con-
formational changes to human serum proteins (Fig. 5C).
After the addition of DODAB:MO (2:1) PegCer0, PegCer5 and
PegCer15 liposomes to the protein solutions, a decrease in the
Fig. 3. STEM micrographs of Peg0, Peg10, PegCer0 and PegCer10 DODAB:MO (2:1) liposome dispersions. Scale bar 1.2 lm.
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the signal, were observed. An example of the interaction of the
liposomes with HSA, at 25 C, is presented in Supplementary infor-
mation (Figs. S4 and S5). The binding constants Kb calculated from
the ﬂuorescence spectra are shown in Fig. 5A. It can be seen that,
for the same temperature, the presence of PEG-Cer decreases the
binding of HSA to liposomes (PegCer0 > PegCer5 > PegCer15). For
the pegylated liposomes, Kb slightly increases from 25 to 30 C,
and then it decreases again for 37 C. For all situations, the calcu-
lated binding sites were between 0.915 and 1.130, which indicates
one possible binding site between HSA and liposomes. Fig. 5B
shows that the Gibbs free energy (DG) calculated for the
interaction between the protein and the liposomes is negative,
meaning that the binding occurs spontaneously. As the tempera-
ture increases, DG becomes slightly more negative for the
non-pegylated liposomes, while this trend is veriﬁed for pegylated
formulations only at 37 C. This suggests that the binding between
liposomes and HSA becomes more spontaneous (DG becomes more
negative) with temperature increase.
In Fig. 5C, it is possible to observe that, although liposomes
interact with HSA (Figs. S4 and S5), none of the siRNA-lipoplexes
tested induced signiﬁcant changes on the tryptophan ﬂuorescence
emission spectra of HSA, ﬁbrinogen and globulins, thus no confor-
mational changes of the serum proteins were induced, at physio-
logical pH, by exposure to lipoplexes.
3.3. PEG-Cer siRNA-lipoplexes induce good cellular responses
The effect of each pegylation strategy was evaluated in terms of
cellular internalization, cytotoxicity and EGFP silencing efﬁciencyof siRNA-lipoplexes in vitro. Additionally, the siRNA-lipoplex bioac-
tivity in a relevant leukemia cell model was assessed for therapeu-
tic BCR-ABL silencing.
EGFP gene silencing efﬁciency, cytotoxicity and cellular inter-
nalization on H1299 cells are depicted in Fig. 6.
The two pegylation strategies had a different impact on gene
silencing efﬁciency of the siRNA-lipoplexes (Fig. 6A): the presence
of 5% (mol:mol) DSPE–PEG drastically decreased EGFP downregu-
lation, while PEG-Cer did not signiﬁcantly inﬂuence it.
The cytotoxicity of the nanocarriers was also evaluated, to
exclude the possibility of a higher toxicity limiting the silencing
effect. The siRNA-lipoplexes did not induce a signiﬁcant cytotoxic
response and no variation was observed across samples (Fig. 6B).
The different pegylation strategies also had a dissimilar impact
on siRNA-lipoplex cellular internalization, resulting in slightly
higher total mean ﬂuorescence intensity (MFI) for PegCer when
compared to Peg lipoplexes (data not shown). Fig. 6C clearly shows
that the presence of DSPE–PEG at the surface of siRNA-lipoplexes
reduced the nanocarriers’ cellular uptake. One should nevertheless
mention that a high number of cells internalized some
siRNA-lipoplexes, for pegylated and non-pegylated DSPE–PEG lipo-
plexes. When siRNA-lipoplexes were post-pegylated with PEG-Cer,
approximately the same levels of ﬂuorescence were detected for all
siRNA-lipoplexes (Fig. 6C). The cellular internalization of
siRNA-lipoplexes was additionally conﬁrmed by CLSM (Fig. 7).
After the 4 h-incubation period, siRNA-lipoplexes were clearly
inside the cytoplasm of the cells, showing a higher internalization
for PegCer when compared to Peg lipoplexes, and therefore corrob-
orating the results obtained by ﬂow cytometry. siRNA-lipoplexes
seem to be localized close the nucleus, but a conclusion about
Fig. 4. DODAB:MO (2:1) siRNA-lipoplexes stability in human serum (HS). (A and B) – siRNA release after siRNA-lipoplexes incubation with HS, as determined by FFS. siRNA-
lipoplexes prepared with Cy5-labeled siRNA, by pre-pegylation with DSPE–PEG (A) or post-pegylation with PEG-Cer (B). Data are presented as mean ± S.D. Statistical
signiﬁcance is highlighted as follow: *p 6 0.05, **p 6 0.01, ***p 6 0.001, relative to 0% PEG, for each time point; and #p 6 0.05, ##p 6 0.01, ###p 6 0.001, relative to HS (0 h), for
each % of PEG. (C and D) – fSPT sizing of PEG-Cer post-pegylated siRNA-lipoplexes in HS. DiIC18(5) oil-labeled lipoplexes were prepared with 0% of PEG-Cer (C) or 5%, 10% and
15% PEG-Cer (D) and incubated in full HS at 37 C. Aliquots were collected for size measurement at time point 0 (t0h), which is represented by the gray line control (Control
(t0h)) and after 2 h, represented by the dark lines. The Control (t0h) on (C) shows the size distribution of PegCer0 immediately after incubation in HS, and the Control (t0h) on
(D) is representative of PegCer5, 10 and 15 immediately after incubation in HS. All siRNA-lipoplexes were prepared at charge ratio (+/) 15.
Fig. 5. PEG-Cer post-pegylated DODAB:MO (2:1) siRNA-lipoplexes interaction with serum proteins. (A and B) – Binding parameters (Kb and DG) calculated for the interaction
of DODAB:MO (2:1) PegCer0, PegCer5, PegCer15 liposomes with human serum albumin (HSA) at pH 7.4. (C) – Changes in the tryptophan emission spectra of the human
proteins albumin, ﬁbrinogen, and globulins, when incubated with DODAB:MO (2:1) siRNA-lipoplexes in PBS, pH 7.4.
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cannot be made (Fig. 6A0–D0).
DODAB:MO (2:1) siRNA-lipoplexes were ﬁnally evaluated on a
relevant humanmyelogenous leukemia cell line. The silencingefﬁciency of DODAB:MO (2:1) siRNA-lipoplexes was determined
by quantitative real time PCR (qPCR) in the K562 cell line, using
BCR-ABL as the gene target. Additionally, the effects of BCR-ABL
downregulation on K562 cell survival were determined by a
Fig. 6. In vitro evaluation of the pegylation strategy of DODAB:MO (2:1) siRNA-
lipoplexes. (A) – EGFP silencing efﬁciency of siRNA-lipoplexes. H1299 eGFP cells
incubated with siRNA-lipoplexes for 4 h and transfection efﬁciency determined
by ﬂow cytometry after 48 h. Control siRNA (siCTRL) and active siRNA (siEGFP)
were used to prepare the lipoplexes, and the percentage of cells with
signiﬁcant knockdown was determined. (B) – Metabolic cytotoxicity induced by
siRNA-lipoplexes. H1299 eGFP cells incubated with siRNA-lipoplexes for 4 h and
MTT assay performed after 48 h. Non-treated cells considered as 100% cell survival.
(C) – Cellular uptake of siRNA-lipoplexes. H1299 eGFFP cells incubated at 37 C with
Cy5-labeled siRNA-lipoplexes, and after 4 h, uptake was determined by ﬂow
cytometry. The mean ﬂuorescence intensity (MFI) of cells treated with Peg0 and
PegCer0 was deﬁned as 100%, % MFI of Peg5, 10 and 15 was calculated against Peg0,
and % MFI of PegCer5, 10 and 15 calculated against PegCer0. siRNA-lipoplexes were
prepared at charge ratio (+/) 15. Data are presented as mean ± S.D. Statistical
signiﬁcance is highlighted as follow: *p 6 0.05, **p 6 0.01, ***p 6 0.001, relative to 0%
PEG, for each type of PEG.
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sion and the percentage of K562 cell survival after treatment with
siRNA-lipoplexes.
BCR-ABL knockdown efﬁciency was evaluated on the K562 cell
line transfected with non-pegylated (PegCer0) and the most pro-
mising post-pegylated DODAB:MO (2:1) siRNA-lipoplex
(PegCer10). This formulation has the required concentration of
PEG to avoid siRNA release (Fig. 4B) and siRNA-lipoplexes aggrega-
tion (Fig. 4D) in human serum. Additionally, the PegCer10
siRNA-lipoplexes are well internalized and have high silencing efﬁ-
ciency on H1299eGFP cells (Fig. 6). The commercial system
Lipofectamine RNAiMax was used as a positive control, and
Peg10 siRNA-lipoplexes were included for comparison. Fig. 8A
shows that all nanocarriers decreased BCR-ABL mRNA levels, with
a higher efﬁciency for PegCer0 lipoplexes and Lipofectamine
RNAiMax. The same result was obtain at the BCR-ABL protein
expression level (Supplementary information, Fig. S6). A decrease
in cell survival was observed 72 h after treatment with PegCer0,
PegCer10 and Lipofectamine RNAiMax encapsulating siBCR-ABL,
but not with liposomes encapsulating scrambled siRNA or emptyliposomes (Fig. 8B). When the effective cell survival was deter-
mined to consider the cytotoxicity induced by the respective
empty vectors, PegCer0 becomes the more effective nanocarrier.4. Discussion
The objective of this work was to optimize DODAB:MO (2:1)
liposomes for systemic siRNA delivery. Our approach to produce
stealth DODAB:MO (2:1) siRNA-lipoplexes was to choose reported
pegylation strategies that have proven to be successful in promot-
ing cell transfection: (i) pre-pegylation with DSPE–PEG and (ii)
post-pegylation with PEG-Cer [23,25]. While DSPE–PEG can be sta-
bly incorporated into the liposome bilayer and provide excellent
stability to liposomes in serum [18], such a stable PEG coating
might interfere with efﬁcient uptake and endosomal escape in
cells. PEG-Cer functionalization, on one hand, provides a less stable
PEG coating with reduced colloidal stability [18] but, on the other,
it has a better chance to maintain cell transfection capabilities.
The pegylation of DODAB:MO (2:1) liposomes/lipoplexes was
successfully achieved with both tested strategies, as demonstrated
by the decrease of the surface charge of the nanocarriers (Table 2).
Additionally, both methods were suitable for the preparation of
homogeneous dispersions of small siRNA-lipoplexes (Table 2,
Fig. 3), independently of the PEG-lipid used, meeting the size
requirements for the prevention of clogging of capillaries and allow
nanocarrier extravasation throughout the fenestrae of capillaries
(400–600 nm) [39–41]. Nevertheless, DSPE–PEG had a more pro-
nounced effect on the f-potential than PEG-Cer, as previously
observed with other formulations [23], and the heating step
required for the incorporation of PEG-Cer chains on the liposomal
membranes inﬂuenced, per se, the surface charge of liposomes. This
result was previously obtained for pDNA delivery systems, where
increasing the temperature from 25 to 50 C promoted the
re-organization of DODAB and MO molecules within the liposomal
formulation, resulting in a positive charge re-localization and con-
sequent f-potential increase [42]. Additionally, it was previously
observed by DSC that the transition temperature (Tm) determined
in the cooling mode is 6 C lower when compared to the Tm deter-
mined in the heating mode, with the same enthalpy [34], suggest-
ing that the heating/cooling process may inﬂuence the liposomes
morphology in an irreversible way. It was also shown before that
increasing the temperature of DODAB:MO (2:1) liposomes had a
similar effect on the nanocarriers morphology as the effect of
increasing the monoolein content of the formulation [29,42].
These previous results [29,34,42], together with the observed
increase in the f-potential of siRNA-lipoplexes (Table 2), as well
as the difference on the percentage of siRNA released from Peg0
and PegCer0 lipoplexes (Fig. 4A and B), support the hypothesis that
increasing the temperature promoted a structural re-organization
of DODAB:MO (2:1) siRNA-lipoplexes. Moreover, the heating step
used to prepare the PEG-Cer coating lead to a better protection
of encapsulated siRNA.
It is well known that gene delivery systems must have speci-
ﬁc characteristics in order to achieve the desired therapeutic
effect. For example, nanocarriers must be able to efﬁciently
encapsulate siRNA and protect it in biological interfaces; should
not aggregate in physiological conditions to prevent clogging of
capillaries, extravasate throughout the fenestrae of capillaries,
as well as avoid immune recognition; must be well internalized
by target cells; and must be able to release their siRNA content
into the cytoplasm for incorporation in the RISC complex. We
have performed a series of experiments in order to evaluate
some of these characteristics, and found that post-pegylation of
DODAB:MO (2:1) lead to a better performance of
siRNA-lipoplexes.
Fig. 7. Uptake of pegylated DODAB:MO (2:1) siRNA-lipoplexes. Intracellular distribution of siRNA-lipoplexes after 4 h incubation with H1299 wild type cells. Lipoplexes were
prepared with Cy5-labeled siRNA (red). A0–D0 display magniﬁcations of cells treated with Peg5 (A), Peg15 (B), PegCer5 (C) and PegCer15 (D) siRNA-lipoplexes, respectively,
showing endo-lysosomal compartments labeled with LysoSensor Green (green) and cell nucleus with Hoechst (blue). Scale bar 10 lm. (For interpretation of the references
to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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not only in HEPES buffer, but also when incubated in human
serum. The mechanism proposed for lipoplex formation suggests
that nucleic acids bind to the surface of the cationic liposomes,
inducing a close contact between nearby liposomes, that ulti-
mately results in the fusion and entrapment of the genetic material
between lipid bilayers [43,44]. In the case of pre-pegylatedlipoplexes, although nucleic acids also bind to liposomal surfaces,
close contact between liposomes is prevented by the PEG-chains,
avoiding fusion and consequent entrapment [45]. As a result,
nucleic acids likely remain at the surface of pegylated liposomes
and are less protected. Our results show that pre-pegylation had
a negative effect on siRNA complexation, as seen by the higher per-
centage of siRNA that is released upon dispersion in HS (cfr.
Fig. 8. Functional effects of BCR-ABL gene silencing by siRNA-lipoplexes. (A) – mRNA level of BCR-ABL expression in K562 cells, as determined 24 h after incubation with
siRNA-lipoplexes by qPCR. GAPDH gene was used as a reference gene. (B) – Percentage of K562 cell survival 72 h after incubation with siRNA-lipoplexes. The percentage of
effective cell survival was determined by normalizing the cytotoxicity obtained after treatment with siBCR-ABL lipoplexes against the empty vectors’ cytotoxicity. n.a. – non
applicable. Results are expressed as mean ± S.D. The ANOVA statistical test was performed, followed by a Dunnett’s post-test. Statistical signiﬁcance is highlighted as follow:
(A) *p 6 0.05, **p 6 0.01, ***p 6 0.001, relative to non-treated cells (NT); (B) *p 6 0.05, **p 6 0.01, ***p 6 0.001, relative to empty vector, and #p 6 0.05, ##p 6 0.01, ###p 6 0.001,
relative to non-treated cells (NT).
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agreement with the values found in literature [12,46]. As Fig. 4 also
demonstrates, pegylated lipoplexes were more susceptible to
siRNA displacement than non-pegylated siRNA-lipoplexes,
although other studies have found that incubation of both
non-pegylated and pegylated siRNA-lipoplexes in full HS released
over 90% siRNA [16]. This displacement is essentially driven by
the high protein concentrations present in serum, as competition
between negatively charged proteins and siRNA molecules for
the positive charges of liposomes is thought to occur [16]. If
siRNA localizes inside of the lipid bilayers, it will be less suscepti-
ble to be displaced by proteins [45]. Studies with polymers have
also shown a more ﬁrm compaction of nucleic acids by PEI
(polyethylenimine) than PEG-PEI, providing a better protection of
siRNA against enzymatic degradation [24]. Post-pegylation
resulted in reduced siRNA displacement because PEG-chains did
not interfere with the siRNA encapsulation, allowing its protection
inside lipid bilayers.
Fig. 4C and D show that PegCer coating is stable enough to pre-
vent aggregation in undiluted human serum for 2 h. Our ﬁndings
agree well with results obtained for other nanocarriers, which
demonstrated aggregation of non-pegylated liposomes and nano-
gels when dispersed in serum [18,19]. But as observed for
DODAB:MO (2:1) siRNA-lipoplexes (Fig. 4), aggregation of nanogels
could be slowed down by modifying their surface with PEG [19].
Our results show that PEG-Cer coating of DODAB:MO (2:1)
siRNA-lipoplexes was able to reduce aggregation in full HS, which
probably is a consequence of a decreased of proteins to the
nanocarriers. Therefore, PegCer liposomes present a better encap-
sulation efﬁciency and siRNA protection than DSPE–PEG lipo-
somes, as well as a good colloidal stability in biological ﬂuids.
siRNA dissociation from lipoplexes before entering the cells will
likely decrease pre-pegylated lipoplexes silencing efﬁciency.
Fig. 6C shows that PegCer lipoplexes are better internalized by
H1299 cells. PEG-Cer reduced less the surface charge of
siRNA-lipoplexes than DSPE–PEG (Table 2), which could account
for enhanced interaction with negatively charged cell membranes
and consequent higher internalization. A better internalization will
deﬁnitely improve the possibility for gene silencing. Actually, in
line with these ﬁndings, our results also showed that the coating
with PEG-Cer was more efﬁcient in promoting EGFP downregula-
tion in H1299 eGPF cells than the coating with DSPE–PEG (Fig. 6A).
One of the main drawbacks of pegylation is the reduction on the
efﬁciency with which lipoplexes can induce escape of siRNA mole-
cules from the endosomes in which they are located after celluptake [25,26]. For non-pegylated lipoplexes the presence of a
helper lipid in the formulation helps on the release of the genetic
material from endosomes [26,46–48], while the presence of PEG
at the nanocarrier surface blocks this release by more than one
mechanism. First, PEG favors a stable lamellar lipid organization,
impairing the modiﬁcation into another structural organization
required for endosomal membrane destabilization [25,49]; second,
PEG also prevents the close interaction between lipoplexes and
endosomal membranes required for destabilization and nucleic
acids release [50]. As stated earlier, stealth strategies with different
PEG moieties will inﬂuence the strength of PEG anchorage to the
liposome bilayer, and this will inﬂuence the de-pegylation process
[51], which in turn controls lipoplexes’ escape from endosomes
and thus the silencing efﬁciency of the system. In the case of
DSPE–PEG, PEG is anchored by DSPE, a zwitterionic phospholipid
with double C18 acyl chains, while in PEG-ceramide the anchorage
is made through ceramide C8 (Fig. 1). The smaller the acyl chains of
the lipids anchored to PEG, the faster the diffusion kinetics [52].
Dialkyl phospholipid residues with C14-C18 hydrocarbon chains
anchored to PEG usually transfer between membranes via mono-
mer diffusion, with half-times of a few tens of hours or less [53].
Consequently, faster de-pegylation is expected to occur for
PegCer siRNA-lipoplexes, probably due to ceramide’s smaller acyl
chains and double bond [52]. Furthermore, since too fast
de-pegylation can compromise the colloidal stability of the system,
the ability of PEG-Cer pegylation to efﬁciently avoid aggregation of
siRNA-lipoplexes in human serum was studied.
The main purpose of pegylation is to decrease binding of pro-
teins to the nanocarriers, which might induce release of the cargo,
aggregation of the nanocarriers and activation of the immune sys-
tem. As expected, at physiological temperature (37 C) not only the
presence of PEG-Cer decreased the binding of HSA when compared
to the non-pegylated liposomes, but also the Kb was lower that the
Kb determined for 25 C. Therefore, the increase in temperature
inﬂuenced the binding process. The increase in temperature
towards the transition temperature of the liposomes (Tm 47.1 C
[34]) lead to the re-organization of DODAB and MO, and has the
same effect as increasing the MO content of liposomes [42].
Therefore, it is expected that a higher mobility induced by MO
can destabilize the liposomes structure, favoring the binding of
proteins even in the presence of PEG. After a certain temperature
(between 30 and 37 C), the lipid rearrangements will allow MO
to adopt a conformation that can stabilize the liposome structure,
decreasing the binding of HSA, not only in the presence of PEG, but
also for the non-pegylated liposomes. Actually, it was previously
A.C.N. Oliveira et al. / Acta Biomaterialia 25 (2015) 216–229 227found that DODAB does not incorporate MO in a very homoge-
neous way, forming DODAB- and MO-rich domains [34].
Therefore, proteins can bind preferentially to one of these regions.
As the temperature increases, the lipid bilayers become more
homogeneous, and MO or DODAB-enriched domains are less fre-
quent, decreasing the interaction with proteins. The fact that the
association between proteins and liposomal membranes is depen-
dent on the membrane structural properties and conditions of
phase separation was already described, in addition to the effect
of the composition of the lipid bilayers [54,55]. The calculated Kb
values were generally <100 lM, indicating strong binding between
the liposomes and the protein.
Not only did we evaluate the binding of proteins to the lipo-
somes, but also the protein conformational changes that
siRNA-lipoplexes induce into human serum proteins, to assure that
protein functions, such as the clottability of ﬁbrinogen, will not be
affected by these interactions. The alteration of the protein ﬂuores-
cence signal can indicate that they are denaturated, as found by
Simón-Vázquez et al. [37] for ZnO nanoparticles. Our results
showed that none of the siRNA-lipoplexes induced signiﬁcant
changes on the tryptophan ﬂuorescence emission spectra of HSA,
ﬁbrinogen and globulins (Fig. 5C). This is another indication of
the biocompatibility of these nanocarriers, together with the fact
that all DODAB:MO (2:1) siRNA-lipoplexes were found to be well
tolerated by the cells (Fig. 6B and Fig. 8B), in line with what was
observed before in other cellular models for MO-based nanocarri-
ers [28,30,34].
The suitability of the pegylated nanocarriers towards a clinical
application was ﬁnally evaluated by measuring the silencing efﬁ-
ciency on a relevant leukemia model cell line, as well as the effect
of the gene downregulation on cell survival. The human myeloge-
nous leukemia cell line K562 expresses the BCR-ABL oncogene, that
results from the t(9;22)(q34;q11) reciprocal translocation between
chromosomes 9 and 22, and causes chronic myeloid leukemia
(CML). BCR-ABL encodes the BCR-ABL protein, a constitutively
active tyrosine kinase, responsible for malignant transformation.
Therefore, silencing BCR-ABL is an approach that is being explored
for CML treatment [56–58]. Our siRNA-lipoplexes were found to
efﬁciently downregulate BCR-ABL gene expression (Fig. 8A), reduce
protein expression (Supplementary information, Fig. S6), and
decrease K562 cell survival (Fig. 8B). Although both pegylation
strategies produced siRNA-lipoplexes able to decrease BCR-ABL
expression, this effect was not translated in a reduction of cell sur-
vival for Peg10 siRNA-lipoplexes. Non-pegylated nanocarriers
achieved higher levels of BCR-ABL gene silencing efﬁciency, but
the silencing effects obtained with pegylated lipoplexes were still
enough to affect K562 survival (Fig. 8B).
Our results show that post-pegylated DODAB:MO (2:1) lipo-
somes encapsulate more siRNA, provide better protection in bio-
logical conditions, do not aggregate in serum, do not induce
conformational changes to serum proteins, are better internalized
by cells, and are apparently more efﬁcient in allowing siRNA
release from endosomes. We believe that the ability to decrease
K562 cell survival, associated with a good stability in human
serum, support PEG-Cer DODAB:MO (2:1) liposomes as promising
siRNA delivery systems for cancer treatment.
Validation of these nanocarriers is currently being prepared in a
murine model of cancer. As demonstrated in the current study,
DODAB:MO (2:1) siRNA-lipoplexes have been designed to obtain
the most favorable physicochemical characteristics for in vivo
application. Speciﬁc gene silencing on a relevant in vitro model
has also been successfully achieved. The proven protection in
serum conferred by liposomes should allow a greater accumulation
of therapeutic siRNA in target cells and consequently reduce dis-
ease burden. Furthermore, in a parallel study, repeated applicationof DODAB:MO liposomes was well tolerated by mice [59] in terms
of toxicity and recognition by the immune system, and the
desired biological effect was reached. Thus, it is expected that a
good clinical response will be obtained for DODAB:MO (2:1)
siRNA-lipoplexes directed against a relevant molecular target in
an in vivo cancer model.5. Conclusions
The success of intravenous siRNA based therapies still depends
on the development of efﬁcient delivery vehicles. In this work we
evaluated two strategies for pegylation of DODAB:MO (2:1) lipo-
somes for siRNA delivery. The siRNA-lipoplexes were evaluated
in vitro, using highly advanced microscopy and spectroscopy tech-
niques, to understand how nanocarriers perform in complex body
ﬂuids before moving to in vivo tests.
The two strategies tested differ on the methodology used to
include PEG onto the nanocarriers (pre and post-pegylation), that
strongly inﬂuenced the siRNA encapsulation efﬁciency and siRNA
protection ability. The use of DSPE–PEG or PEG-Cer had an impact
on the kinetics of PEG release from the liposomes, which inﬂu-
enced the nanocarriers’ stability in serum, cellular uptake and
silencing activity of the systems.
DODAB:MO (2:1) post-pegylated with PEG-Cer resulted in bet-
ter siRNA protection from displacement by serum proteins, better
cellular internalization, and superior silencing efﬁciency.
Additionally, the PEG-Cer nanocarriers had the ability to reduce
binding of HSA to liposomes, slowing down aggregation in human
serum, and had the potential to silence the BCR-ABL gene in a
leukemia cell line model, affecting cellular survival. Taking in
consideration all the results, surface modiﬁcation with
PEG-Cer post-pegylation is suggested as a promising strategy for
the in vivo successful application of DODAB:MO (2:1)
siRNA-lipoplexes. Other published results by our group in mouse
models [59] also lead us to believe the systemwill be well tolerated
in vivo. The clinical usefulness of these vectors will soon be vali-
dated in an in vivo murine cancer model.Disclosures
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